The incidence of tuberculosis recurrence: Impacts of treatment duration of and adherence to standard anti-tuberculous therapy

被引:1
作者
Lee, Chung-Shu [1 ,2 ]
Ho, Chung-Han [3 ,4 ,5 ]
Liao, Kuang-Ming [6 ]
Wu, Yu-Cih [3 ]
Shu, Chin-Chung [7 ,8 ]
机构
[1] New Taipei Municipal TuCheng Hosp, Dept Pulm & Crit Care Med, New Taipei City, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp, Sch Med, Dept Thorac Med, Taipei, Taiwan
[3] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan
[4] Southern Taiwan Univ Sci & Technol, Dept Informat Management, Tainan, Taiwan
[5] Taipei Med Univ, Taipei Municipal Wanfang Hosp, Canc Ctr, Taipei, Taiwan
[6] Chi Mei Med Ctr, Dept Internal Med, Chiali, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[8] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
关键词
Complete adherence; TB recurrence; Treatment duration; Tuberculosis; PREVENTION/INFECTIOUS DISEASES SOCIETY; AMERICAN THORACIC SOCIETY/CENTERS; PRACTICE GUIDELINES TREATMENT; DRUG-RESISTANCE; REGIMENS;
D O I
10.1016/j.jiph.2023.09.005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: We investigated the impacts of the standard treatment durations of and adherence to standard anti-tuberculous therapy (ATT) on recurrence after the successful completion of tuberculosis (TB) treatment.Methods: We recruited patients with TB who had received treatment for six or nine months from the 2008-2017 databases of the Taiwanese National Health Insurance Research Database. Treatment duration and adherence to standard ATT were analyzed for their impacts on recurrence within two years. Complete adherence to standard ATT was defined as daily use of ethambutol, isoniazid, pyrazinamide, and rifampin for the first two months, and daily use of isoniazid and rifampin for the first six months.Results: A total of 33,298 TB patients with new-onset TB were identified and classified into two groups by treatment duration: six months (n = 25,849, 77.63%) and nine months (n = 7449). Sex and age distributions varied between the groups. Treatment duration did not affect TB recurrence within two years (adjusted hazard ratio (AHR): 1.18, 95% confidence interval (C.I.) [0.96-1.4 4], p = 0.1156). Multivariable logistic regression showed that incomplete adherence to standard anti-tuberculous therapy (80-89% and 90-99% standard anti-TB therapy, AHR: 1.57, 95% C.I. [1.26-1.95], and 1.63, 95% C.I. [1.26-2.06], respectively, p < 0.0001) increased TB recurrence. In addition, male sex, older age, and comorbidity with diabetes mellitus or chronic obstructive pulmonary disease were independent risk factors for TB recurrence within two years.Conclusions: TB recurrence was 1.54% within two years under a DOT era. TB treatment durations of six or nine months did not affect TB recurrence within two years after completion of TB treatment, but incomplete adherence to standard anti-tuberculous therapy might increase the TB recurrence rate.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/li-censes/by-nc-nd/4.0/).
引用
收藏
页码:1778 / 1783
页数:6
相关论文
共 33 条
  • [21] Treatment Strategy for Rifampin-Susceptible Tuberculosis
    Paton, Nicholas I.
    Cousins, Christopher
    Suresh, Celina
    Burhan, Erlina
    Chew, Ka Lip
    Dalay, Victoria B.
    Lu, Qingshu
    Kusmiati, Tutik
    Balanag, Vincent M.
    Lee, Shu Ling
    Ruslami, Rovina
    Pokharkar, Yogesh
    Djaharuddin, Irawaty
    Sugiri, Jani J. R.
    Veto, Rholine S.
    Sekaggya-Wiltshire, Christine
    Avihingsanon, Anchalee
    Sarin, Rohit
    Papineni, Padmasayee
    Nunn, Andrew J.
    Crook, Angela M.
    TRUNCATE-TB Trial Team
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (10) : 873 - 887
  • [22] Pinto Lancelot, 2011, Infect Drug Resist, V4, P129, DOI 10.2147/IDR.S10332
  • [23] Prevention CoDCa, 2022, Tuberculosis (TB)
  • [24] Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes
    Ramachandran, Geetha
    Chandrasekaran, Padmapriyadarshini
    Gaikwad, Sanjay
    Kumar, Hemanth
    Thiruvengadam, Kannan
    Gupte, Nikhil
    Paradkar, Mandar S.
    Dhanasekaran, Kavitha
    Sivaramakrishnan, Gomathi Narayan
    Kagal, Anju
    Thomas, Beena
    Pradhan, Neeta
    Kadam, Dileep
    Hanna, Luke Elizabeth
    Balasubramanian, Usha
    Kulkarni, Vandana
    Murali, Lakshmi
    Golub, Jonathan
    Gupte, Akshay N.
    Shivakumar, Shri Vijay Bala Yogendra
    Swaminathan, Soumya
    Dooley, Kelly E.
    Gupta, Amita
    Mave, Vidya
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 70 (07) : 1463 - 1470
  • [25] Recurrent tuberculosis in the pre-elimination era
    Rosser, A.
    Marx, F. M.
    Pareek, M.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (02) : 139 - +
  • [26] Increasing drug resistance of Mycobacterium tuberculosis isolates in a medical center in northern Taiwan
    Su, Wei-Juin
    Feng, Jia-Yih
    Huang, Chin-Chou
    Perng, Reury-Perng
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2008, 107 (03) : 259 - 264
  • [27] Understanding Nonadherence to Tuberculosis Medications in India Using Urine Drug Metabolite Testing: A Cohort Study
    Subbaraman, Ramnath
    Thomas, Beena E.
    Kumar, J. Vignesh
    Thiruvengadam, Kannan
    Khandewale, Amit
    Kokila, S.
    Lubeck-Schricker, Maya
    Kumar, M. Ranjith
    Gaurkhede, Gunjan Rahul
    Walgude, Apurva Shashikant
    Mercy, J. Hephzibah
    Kumbhar, Jagannath Dattatraya
    Eliasziw, Misha
    Mayer, Kenneth H.
    Haberer, Jessica E.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (06):
  • [28] Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
    Tiberi, Simon
    du Plessis, Nelita
    Walzl, Gerhard
    Vjecha, Michael J.
    Rao, Martin
    Ntoumi, Francine
    Mfinanga, Sayoki
    Kapata, Nathan
    Mwaba, Peter
    McHugh, Timothy D.
    Ippolito, Giuseppe
    Migliori, Giovanni Battista
    Maeurer, Markus J.
    Zumla, Alimuddin
    [J]. LANCET INFECTIOUS DISEASES, 2018, 18 (07) : E183 - E198
  • [29] Optimal Duration of Anti-TB Treatment in Patients With Diabetes Nine or Six Months?
    Wang, Jann-Yuan
    Lee, Ming-Chia
    Shu, Chin-Chung
    Lee, Chih-Hsin
    Lee, Li-Na
    Chao, Kun-Mao
    Chang, Feng-Yee
    [J]. CHEST, 2015, 147 (02) : 520 - 528
  • [30] THE EFFECT OF DIRECTLY OBSERVED THERAPY ON THE RATES OF DRUG-RESISTANCE AND RELAPSE IN TUBERCULOSIS
    WEIS, SE
    SLOCUM, PC
    BLAIS, FX
    KING, B
    NUNN, M
    MATNEY, GB
    GOMEZ, E
    FORESMAN, BH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (17) : 1179 - 1184